Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant | Molecular Pharmaceutics
Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein | PNAS
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) - ScienceDirect
Cureus | KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer | Article
Frontiers | The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
Cancers | Free Full-Text | KRAS in NSCLC: State of the Art and Future Perspectives
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Notorious KRAS: Taking down cancer researchers' biggest foe
Small molecule combats cancer-causing KRAS protein at last
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors | PNAS
Frontiers | Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
KRAS - Wikipedia
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM
KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib - Lacasta‐Plasin - 2021 - Clinical Genetics - Wiley Online Library
KRAS: feeding pancreatic cancer proliferation: Trends in Biochemical Sciences
Targeting mutated GTPase KRAS in tumor therapies - ScienceDirect
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance: Trends in Cancer
